Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.

Created on 28 Jul 2026

Authors

Takehiro Tanaka, Toyohito Oriyama, Takehito Yamamoto, Saori Kimura, Alice Fujii, Riri Tauchi, Kyoko Shirai, Satoru Taguchi, Taketo Kawai, Haruki Kume, Tappei Takada

Published in

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Volume 34. Issue 8. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Chemotherapy-induced (CI) dysgeusia is a common adverse event that impairs nutritional status and quality of life; however, its risk factors remain poorly understood. This study aimed to identify risk factors for CI dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) therapy.
We conducted a single-center retrospective observational study including patients with urothelial carcinoma who received dd-MVAC therapy between August 2018 and March 2023. CI dysgeusia was defined as grade ≥ 2 dysgeusia according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Univariable logistic regression was performed to screen candidate predictors (p < 0.20), followed by multivariable logistic regression with backward stepwise selection. Cutoff values were determined using receiver operating characteristic (ROC) analysis. Predictive performance was evaluated using positive predictive value (PPV) and negative predictive value (NPV).
Among 103 patients, 32 (31.1%) developed CI dysgeusia. Multivariable analysis identified depression (adjusted odds ratio [aOR] 23.3, 95% CI 3.01-529; p = 0.010) and HbA1c ≤ 5.8% (aOR 2.86, 95% CI 1.16-7.30; p = 0.024) as independent risk factors. Depression alone showed good predictive performance (PPV 83.3%; NPV 72.2%) and combining it with HbA1c ≤ 5.8% increased PPV to 100%.
Depression and HbA1c ≤ 5.8% were independent risk factors for CI dysgeusia in patients undergoing dd-MVAC therapy. These findings suggest that readily available clinical information may enable early identification of high-risk patients and support individualized supportive care strategies.

PMID:
42517935
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement